Until now, only one study has addressed GLP1 agonist treatment in PCOS, providing evidence that combined treatment with short-acting GLP1 receptor agonist exenatide and metformin was superior to exenatide and metformin monotherapies in improving menstrual cyclicity, ovulation rate, androgens, insulin sensitivity measures, and weight loss (11). The gene discussed is GLP1R; the disease is polycystic ovary syndrome.